SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update

SCYNEXIS, Inc. (NASDAQ:SCYX) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 678,500 shares, a decrease of 14.7% from the November 30th total of 795,400 shares. Based on an average daily volume of 163,900 shares, the short-interest ratio is presently 4.1 days.

SCYNEXIS Trading Down 2.0 %

Shares of SCYNEXIS stock opened at $1.00 on Monday. The stock has a market capitalization of $37.92 million, a price-to-earnings ratio of -1.35 and a beta of 1.50. SCYNEXIS has a twelve month low of $0.90 and a twelve month high of $3.07. The business’s 50 day simple moving average is $1.24 and its 200-day simple moving average is $1.57.

SCYNEXIS (NASDAQ:SCYX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.14. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The firm had revenue of $0.66 million for the quarter. Sell-side analysts predict that SCYNEXIS will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of SCYNEXIS from a “sell” rating to a “hold” rating in a report on Friday, November 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in shares of SCYNEXIS by 10.0% during the third quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock valued at $594,000 after buying an additional 36,405 shares during the last quarter. XTX Topco Ltd bought a new stake in SCYNEXIS during the 3rd quarter valued at $25,000. Finally, Acadian Asset Management LLC raised its stake in SCYNEXIS by 28.4% during the 2nd quarter. Acadian Asset Management LLC now owns 540,683 shares of the company’s stock valued at $1,080,000 after acquiring an additional 119,600 shares in the last quarter. 54.37% of the stock is owned by institutional investors and hedge funds.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.